LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Human IVIG treatment in a neurological disease model for Enterovirus A71 infection in 28-day-old AG129 mice.

    Peterson, Christopher J / Hurst, Brett L / Evans, W Joseph / Van Wettere, Arnaud J / Gibson, Scott A / Smee, Donald F / Tarbet, E Bart

    Virology

    2023  Volume 580, Page(s) 62–72

    Abstract: Enterovirus A71 can cause serious neurological disease in young children. Animal models for EV-A71 are needed to evaluate potential antiviral therapies. Existing models have limitations, including lack of lethality or crucial disease signs. Here we ... ...

    Abstract Enterovirus A71 can cause serious neurological disease in young children. Animal models for EV-A71 are needed to evaluate potential antiviral therapies. Existing models have limitations, including lack of lethality or crucial disease signs. Here we report the development of an EV-A71 model in 28-day-old mice. Virus was serially passaged until it produced consistent lethality and rear-limb paralysis. Onset of disease occurred between days 6-9 post-infection, with mortality following weight loss and neurological signs on days 9-14. In addition, a single administration of human intravenous immunoglobulin at doses of 200, 400 and 800 mg/kg at 4h post-infection was evaluated in the model. Protection from weight loss, neurological signs, and mortality (between 50 and 89%) were observed at doses of 400 mg/kg or greater. Based on these results, IVIG was selected for use as a positive control in this acute model, and suggest that IVIG is a potential therapeutic for EV-A71 infections.
    MeSH term(s) Child ; Humans ; Mice ; Animals ; Child, Preschool ; Immunoglobulins, Intravenous/therapeutic use ; Enterovirus Infections ; Enterovirus ; Enterovirus A, Human ; Nervous System Diseases ; Disease Models, Animal
    Chemical Substances Immunoglobulins, Intravenous
    Language English
    Publishing date 2023-02-04
    Publishing country United States
    Document type Journal Article ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 200425-2
    ISSN 1096-0341 ; 0042-6822
    ISSN (online) 1096-0341
    ISSN 0042-6822
    DOI 10.1016/j.virol.2023.02.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Human IVIG treatment in a neurological disease model for Enterovirus A71 infection in 28-day-old AG129 mice

    Peterson, Christopher J. / Hurst, Brett L. / Evans, W. Joseph / Van Wettere, Arnaud J. / Gibson, Scott A. / Smee, Donald F. / Tarbet, E. Bart

    Virology. 2023 Feb. 04,

    2023  

    Abstract: Enterovirus A71 can cause serious neurological disease in young children. Animal models for EV-A71 are needed to evaluate potential antiviral therapies. Existing models have limitations, including lack of lethality or crucial disease signs. Here we ... ...

    Abstract Enterovirus A71 can cause serious neurological disease in young children. Animal models for EV-A71 are needed to evaluate potential antiviral therapies. Existing models have limitations, including lack of lethality or crucial disease signs. Here we report the development of an EV-A71 model in 28-day-old mice. Virus was serially passaged until it produced consistent lethality and rear-limb paralysis. Onset of disease occurred between days 6–9 post-infection, with mortality following weight loss and neurological signs on days 9–14. In addition, a single administration of human intravenous immunoglobulin at doses of 200, 400 and 800 mg/kg at 4h post-infection was evaluated in the model. Protection from weight loss, neurological signs, and mortality (between 50-89%) were observed at doses of 400 mg/kg or greater. Based on these results, IVIG was selected for use as a positive control in this acute model, and suggest that IVIG is a potential therapeutic for EV-A71 infections.
    Keywords Enterovirus A ; death ; disease models ; humans ; immunoglobulins ; intravenous injection ; mortality ; nervous system diseases ; paralysis ; virology ; viruses ; weight loss ; Enterovirus A71 ; Animal model ; Neurological disease ; AG129 ; Intravenous immunoglobulin ; Therapeutics
    Language English
    Dates of publication 2023-0204
    Size p. 62-72.
    Publishing place Elsevier Inc.
    Document type Article ; Online
    Note Pre-press version
    ZDB-ID 200425-2
    ISSN 1096-0341 ; 0042-6822
    ISSN (online) 1096-0341
    ISSN 0042-6822
    DOI 10.1016/j.virol.2023.02.002
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  3. Article ; Online: A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19.

    Allerton, Charlotte M N / Arcari, Joel T / Aschenbrenner, Lisa M / Avery, Melissa / Bechle, Bruce M / Behzadi, Mohammad Amin / Boras, Britton / Buzon, Leanne M / Cardin, Rhonda D / Catlin, Natasha R / Carlo, Anthony A / Coffman, Karen J / Dantonio, Alyssa / Di, Li / Eng, Heather / Farley, Kathleen A / Ferre, Rose Ann / Gernhardt, Steven S / Gibson, Scott A /
    Greasley, Samantha E / Greenfield, Siennah R / Hurst, Brett L / Kalgutkar, Amit S / Kimoto, Emi / Lanyon, Lorraine F / Lovett, Gabrielle H / Lian, Yajing / Liu, Wei / Martínez Alsina, Luis A / Noell, Stephen / Obach, R Scott / Owen, Dafydd R / Patel, Nandini C / Rai, Devendra K / Reese, Matthew R / Rothan, Hussin A / Sakata, Sylvie / Sammons, Matthew F / Sathish, Jean G / Sharma, Raman / Steppan, Claire M / Tuttle, Jamison B / Verhoest, Patrick R / Wei, Liuqing / Yang, Qingyi / Yurgelonis, Irina / Zhu, Yuao

    Journal of medicinal chemistry

    2024  

    Abstract: Despite the record-breaking discovery, development and approval of vaccines and antiviral therapeutics such as Paxlovid, coronavirus disease 2019 (COVID-19) remained the fourth leading cause of death in the world and third highest in the United States in ...

    Abstract Despite the record-breaking discovery, development and approval of vaccines and antiviral therapeutics such as Paxlovid, coronavirus disease 2019 (COVID-19) remained the fourth leading cause of death in the world and third highest in the United States in 2022. Here, we report the discovery and characterization of PF-07817883, a second-generation, orally bioavailable, SARS-CoV-2 main protease inhibitor with improved metabolic stability versus nirmatrelvir, the antiviral component of the ritonavir-boosted therapy Paxlovid. We demonstrate the
    Language English
    Publishing date 2024-04-30
    Publishing country United States
    Document type Journal Article
    ZDB-ID 218133-2
    ISSN 1520-4804 ; 0022-2623
    ISSN (online) 1520-4804
    ISSN 0022-2623
    DOI 10.1021/acs.jmedchem.3c02469
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2.

    Hagey, Rachel J / Elazar, Menashe / Pham, Edward A / Tian, Siqi / Ben-Avi, Lily / Bernardin-Souibgui, Claire / Yee, Matthew F / Moreira, Fernando R / Rabinovitch, Meirav Vilan / Meganck, Rita M / Fram, Benjamin / Beck, Aimee / Gibson, Scott A / Lam, Grace / Devera, Josephine / Kladwang, Wipapat / Nguyen, Khanh / Xiong, Anming / Schaffert, Steven /
    Avisar, Talia / Liu, Ping / Rustagi, Arjun / Fichtenbaum, Carl J / Pang, Phillip S / Khatri, Purvesh / Tseng, Chien-Te / Taubenberger, Jeffery K / Blish, Catherine A / Hurst, Brett L / Sheahan, Timothy P / Das, Rhiju / Glenn, Jeffrey S

    Nature medicine

    2022  Volume 28, Issue 9, Page(s) 1944–1955

    Abstract: Influenza A virus's (IAV's) frequent genetic changes challenge vaccine strategies and engender resistance to current drugs. We sought to identify conserved and essential RNA secondary structures within IAV's genome that are predicted to have greater ... ...

    Abstract Influenza A virus's (IAV's) frequent genetic changes challenge vaccine strategies and engender resistance to current drugs. We sought to identify conserved and essential RNA secondary structures within IAV's genome that are predicted to have greater constraints on mutation in response to therapeutic targeting. We identified and genetically validated an RNA structure (packaging stem-loop 2 (PSL2)) that mediates in vitro packaging and in vivo disease and is conserved across all known IAV isolates. A PSL2-targeting locked nucleic acid (LNA), administered 3 d after, or 14 d before, a lethal IAV inoculum provided 100% survival in mice, led to the development of strong immunity to rechallenge with a tenfold lethal inoculum, evaded attempts to select for resistance and retained full potency against neuraminidase inhibitor-resistant virus. Use of an analogous approach to target SARS-CoV-2, prophylactic administration of LNAs specific for highly conserved RNA structures in the viral genome, protected hamsters from efficient transmission of the SARS-CoV-2 USA_WA1/2020 variant. These findings highlight the potential applicability of this approach to any virus of interest via a process we term 'programmable antivirals', with implications for antiviral prophylaxis and post-exposure therapy.
    MeSH term(s) Animals ; Antiviral Agents/pharmacology ; Influenza A virus/genetics ; Mice ; Neuraminidase ; RNA, Viral/genetics ; SARS-CoV-2 ; COVID-19 Drug Treatment
    Chemical Substances Antiviral Agents ; RNA, Viral ; Neuraminidase (EC 3.2.1.18)
    Language English
    Publishing date 2022-08-18
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Intramural ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 1220066-9
    ISSN 1546-170X ; 1078-8956
    ISSN (online) 1546-170X
    ISSN 1078-8956
    DOI 10.1038/s41591-022-01908-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: An oral SARS-CoV-2 M

    Owen, Dafydd R / Allerton, Charlotte M N / Anderson, Annaliesa S / Aschenbrenner, Lisa / Avery, Melissa / Berritt, Simon / Boras, Britton / Cardin, Rhonda D / Carlo, Anthony / Coffman, Karen J / Dantonio, Alyssa / Di, Li / Eng, Heather / Ferre, RoseAnn / Gajiwala, Ketan S / Gibson, Scott A / Greasley, Samantha E / Hurst, Brett L / Kadar, Eugene P /
    Kalgutkar, Amit S / Lee, Jack C / Lee, Jisun / Liu, Wei / Mason, Stephen W / Noell, Stephen / Novak, Jonathan J / Obach, R Scott / Ogilvie, Kevin / Patel, Nandini C / Pettersson, Martin / Rai, Devendra K / Reese, Matthew R / Sammons, Matthew F / Sathish, Jean G / Singh, Ravi Shankar P / Steppan, Claire M / Stewart, Al E / Tuttle, Jamison B / Updyke, Lawrence / Verhoest, Patrick R / Wei, Liuqing / Yang, Qingyi / Zhu, Yuao

    Science (New York, N.Y.)

    2021  Volume 374, Issue 6575, Page(s) 1586–1593

    Abstract: The worldwide outbreak of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. Alongside vaccines, antiviral therapeutics are an important part of the healthcare response to countering the ongoing ... ...

    Abstract The worldwide outbreak of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. Alongside vaccines, antiviral therapeutics are an important part of the healthcare response to countering the ongoing threat presented by COVID-19. Here, we report the discovery and characterization of PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. PF-07321332 has demonstrated oral activity in a mouse-adapted SARS-CoV-2 model and has achieved oral plasma concentrations exceeding the in vitro antiviral cell potency in a phase 1 clinical trial in healthy human participants.
    MeSH term(s) Administration, Oral ; Animals ; COVID-19/drug therapy ; COVID-19/virology ; Clinical Trials, Phase I as Topic ; Coronavirus/drug effects ; Disease Models, Animal ; Drug Therapy, Combination ; Humans ; Lactams/administration & dosage ; Lactams/pharmacokinetics ; Lactams/pharmacology ; Lactams/therapeutic use ; Leucine/administration & dosage ; Leucine/pharmacokinetics ; Leucine/pharmacology ; Leucine/therapeutic use ; Mice ; Mice, Inbred BALB C ; Microbial Sensitivity Tests ; Nitriles/administration & dosage ; Nitriles/pharmacokinetics ; Nitriles/pharmacology ; Nitriles/therapeutic use ; Proline/administration & dosage ; Proline/pharmacokinetics ; Proline/pharmacology ; Proline/therapeutic use ; Randomized Controlled Trials as Topic ; Ritonavir/administration & dosage ; Ritonavir/therapeutic use ; SARS-CoV-2/drug effects ; SARS-CoV-2/physiology ; Viral Protease Inhibitors/administration & dosage ; Viral Protease Inhibitors/pharmacokinetics ; Viral Protease Inhibitors/pharmacology ; Viral Protease Inhibitors/therapeutic use ; Virus Replication/drug effects
    Chemical Substances Lactams ; Nitriles ; Viral Protease Inhibitors ; nirmatrelvir (7R9A5P7H32) ; Proline (9DLQ4CIU6V) ; Leucine (GMW67QNF9C) ; Ritonavir (O3J8G9O825)
    Language English
    Publishing date 2021-11-02
    Publishing country United States
    Document type Journal Article
    ZDB-ID 128410-1
    ISSN 1095-9203 ; 0036-8075
    ISSN (online) 1095-9203
    ISSN 0036-8075
    DOI 10.1126/science.abl4784
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: An Oral SARS-CoV-2 Mpro Inhibitor Clinical Candidate for the Treatment of COVID-19

    Owen, Dafydd R / Allerton, Charlotte M N / Anderson, Annaliesa S / Aschenbrenner, Lisa / Avery, Melissa / Berritt, Simon / Boras, Britton / Cardin, Rhonda D / Carlo, Anthony / Coffman, Karen / Dantonio, Alyssa / Di, Li / Eng, Heather / Ferre, RoseAnn / Gajiwala, Ketan S / Gibson, Scott A / Greasley, Samantha E / Hurst, Brett L / Kadar, Eugene P /
    Kalgutkar, Amit S / Lee, Jack C / Lee, Jisun / Liu, Wei / Mason, Stephen W / Noell, Stephen / Novak, Jonathan J / Obach, R Scott / Ogilvie, Kevin / Patel, Nandini C / Pettersson, Martin / Rai, Devendra K / Reese, Matthew R / Sammons, Matthew F / Sathish, Jean G / Singh, Ravi Shankar P / Steppan, Claire M / Stewart, Al E / Tuttle, Jamison B / Updyke, Lawrence / Verhoest, Patrick R / Wei, Liuqing / Yang, Qingyi / Zhu, Yuao

    medRxiv

    Abstract: The worldwide outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become an established global pandemic. Alongside vaccines, antiviral therapeutics are an important part of the ... ...

    Abstract The worldwide outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become an established global pandemic. Alongside vaccines, antiviral therapeutics are an important part of the healthcare response to counter the ongoing threat presented by COVID-19. Here, we report the discovery and characterization of PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor with in vitro pan-human coronavirus antiviral activity, and excellent off-target selectivity and in vivo safety profiles. PF-07321332 has demonstrated oral activity in a mouse-adapted SARS-CoV-2 model and has achieved oral plasma concentrations exceeding the in vitro antiviral cell potency, in a phase I clinical trial in healthy human participants. Clinical Trial Registration ID #: NCT04756531
    Keywords covid19
    Language English
    Publishing date 2021-07-31
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2021.07.28.21261232
    Database COVID19

    Kategorien

To top